Vericiguat suspension clinical trials

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

This study is looking at a new medicine called vericiguat for children and young people aged 29 days to 17 years with heart failure. We want to see if it can improve their heart health compared to a dummy medicine.